Limited Edition Golden Llama is here! Check out how you can get one. Limited Edition Golden Llama is here! Check out how you can get one.
Offering SPR-BLI Services - Proteins provided for free! Get your ComboX free sample to test now!
Time Limited Offer: Welcome Gift for New Customers ! Shipping Price Reduction for EU Regions
Cat . Non | Espèces | Description du produit | Structure | Pureté | Caractéristique |
---|---|---|---|---|---|
APP-H52H3 | Human | Human APP Protein, His Tag (active enzyme, MALS verified) |
|
||
CHEK-ATP081 | Human | HEK293/Human APP (GFP) Stable Cell Line | |||
APP-H51H7 | Human | Human APP / Abeta40 Protein, His Tag |
|
||
APP-H52H5 | Human | Human APP / SAPPbeta Protein, His Tag (MALS verified) |
|
||
APP-M52H3 | Mouse | Mouse APP / N-APP Protein, His Tag (MALS verified) |
|
FACS analysis of APP (GFP) on HEK293/Human APP (GFP) Stable Cell Line.
HEK293/Human APP (GFP) Stable Cell Line was red line, negative control HEK293 cells was grey line (QC tested).
The purity of Human APP Protein, His Tag (Cat. No. APP-H52H3) is more than 85% and the molecular weight of this protein is around 80-110 kDa verified by SEC-MALS.
The purity of Human SAPPbeta, His Tag (Cat. No. APP-H52H5) is more than 90% and the molecular weight of this protein is around 95-115 kDa verified by SEC-MALS.
Please contact us via TechSupport@acrobiosystems.com if you have any question on this product.
Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
---|---|---|---|---|---|---|---|---|---|---|
Sodium Oligomannurarate | GV-971; 971 | Approved | Ocean University Of China, Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences | 九期一 | Mainland China | Alzheimer Disease | Shanghai Greenvalley Pharmaceutical Co Ltd | 2019-11-02 | Parkinson Disease; Cognitive Dysfunction; Alzheimer Disease | Details |
Flutemetamol (18F) | AH-110690; GE-067; 18F-GE067 | Approved | Ge Healthcare | Vizamyl | United States | Contrast agents | Ge Healthcare | 2013-10-25 | Atherosclerosis; Cardiomyopathies; Breast Neoplasms; Contrast agents; Cognitive Dysfunction; Alzheimer Disease; Dementia; Diagnostic agents; Hydrocephalus, Normal Pressure; Cognition Disorders | Details |
Inositol | 4L6452S749 | Approved | Nicosit | Infant, Newborn, Diseases; Precancerous Conditions; Hyperandrogenism; Carcinoma, Non-Small-Cell Lung; Infant, Premature, Diseases; Retinopathy of Prematurity; Lung Neoplasms; Metabolic Diseases; Bronchopulmonary Dysplasia; Anovulation; Diabetic Neuropathies; Insulin Resistance; Glucose Intolerance; Polycystic Ovary Syndrome; Small Cell Lung Carcinoma; Anxiety; Depression | Details | |||||
Immune globulin 10% (Grifols) | KIg-10; TAL-05-0002 | Approved | Bayer AG | Gamunex, Gammaked | United States | Polyradiculoneuropathy, Chronic Inflammatory Demyelinating; Purpura, Thrombocytopenic, Idiopathic; Immunologic Deficiency Syndromes | null | 2003-08-27 | Anxiety Disorders; Corneal Neovascularization; Immunologic Deficiency Syndromes; Kidney Failure, Chronic; Muscular Diseases; Common Variable Immunodeficiency; Neuralgia; Obsessive-Compulsive Disorder; Reflex Sympathetic Dystrophy; Severe Combined Immunodeficiency; Wiskott-Aldrich Syndrome; Autoimmune Diseases; Postural Orthostatic Tachycardia Syndrome; Coronavirus Disease 2019 (COVID-19); Agammaglobulinemia; Tibial Fractures; Primary Immunodeficiency Diseases; Purpura, Thrombocytopenic, Idiopathic; Polyradiculoneuropathy, Chronic Inflammatory Demyelinating; Myasthenia Gravis | Details |
Florapronol (18F) | 18F-FC-119S; 18F-FC-119(S) | Approved | Korea Institute Of Radiological And Medical Sciences, Futurechem | Alzavue | Alzheimer Disease | Details | ||||
Aducanumab | BIIB-037; NI-10; BART | Approved | Neurimmune Ag | ADUHELM | United States | Alzheimer Disease | Biogen Inc | 2021-06-07 | Cognitive Dysfunction; Dementia; Alzheimer Disease | Details |
L-Lysine hydrochloride/Cyanocobalamin/Inositol | Approved | 兴邦 | Malnutrition | Details | ||||||
Immune Globulin Subcutaneous (Human) (Octapharma) | Approved | Octapharma | Cutaquig, Octanorm, Gammanorm | United States | Immunologic Deficiency Syndromes | null | 2018-08-02 | Primary Immunodeficiency Diseases; Dermatomyositis; Immunologic Deficiency Syndromes | Details | |
Florbetaben (18F) | MNI-815; AV-1; ZK-6013443; BAY-949172; 18F-AV-1; 18F-AV1/ZK; AV-1/ZK; BAY 94-9172; UNII-TLA7312TOI | Approved | Piramal | Neuraceq, 欧韦宁 | EU | Alzheimer Disease | Life Radiopharma Berlin Gmbh | 2014-02-20 | Supranuclear Palsy, Progressive; Down Syndrome; Hyponatremia; Immunoglobulin Light-chain Amyloidosis; Contrast agents; Amyloidosis; Alzheimer Disease; Dementia | Details |
Lecanemab | BAN-2401 | Approved | Bioarctic Neuroscience | Leqembi, 乐意保, LEQEMBI | United States | Alzheimer Disease | Eisai Inc | 2023-01-06 | Alzheimer Disease; Cognitive Dysfunction; Dementia | Details |
Florbetapir(18F) | MNI-798; AV-45 | Approved | Eli Lilly And Company | Amyvid | United States | Spasms, Infantile; Rheumatic Diseases; Respiration Disorders; Multiple Sclerosis; Eye Diseases; Collagen Diseases; Skin Diseases; Hypersensitivity | Avid Radiopharmaceuticals Inc | 2012-04-06 | Amyloidosis; Hypersensitivity; Frontotemporal Dementia; Neurodegenerative Diseases; Collagen Diseases; Eye Diseases; Lewy Body Disease; Diagnostic agents; Parkinson Disease; Respiration Disorders; Alzheimer Disease; Rheumatic Diseases; Cognitive Dysfunction; Contrast agents; Spasms, Infantile; Skin Diseases; Multiple Sclerosis; Glioblastoma | Details |
Sodium Oligomannurarate | GV-971; 971 | Approved | Ocean University Of China, Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences | 九期一 | Mainland China | Alzheimer Disease | Shanghai Greenvalley Pharmaceutical Co Ltd | 2019-11-02 | Parkinson Disease; Cognitive Dysfunction; Alzheimer Disease | Details |
Flutemetamol (18F) | AH-110690; GE-067; 18F-GE067 | Approved | Ge Healthcare | Vizamyl | United States | Contrast agents | Ge Healthcare | 2013-10-25 | Atherosclerosis; Cardiomyopathies; Breast Neoplasms; Contrast agents; Cognitive Dysfunction; Alzheimer Disease; Dementia; Diagnostic agents; Hydrocephalus, Normal Pressure; Cognition Disorders | Details |
Inositol | 4L6452S749 | Approved | Nicosit | Infant, Newborn, Diseases; Precancerous Conditions; Hyperandrogenism; Carcinoma, Non-Small-Cell Lung; Infant, Premature, Diseases; Retinopathy of Prematurity; Lung Neoplasms; Metabolic Diseases; Bronchopulmonary Dysplasia; Anovulation; Diabetic Neuropathies; Insulin Resistance; Glucose Intolerance; Polycystic Ovary Syndrome; Small Cell Lung Carcinoma; Anxiety; Depression | Details | |||||
Immune globulin 10% (Grifols) | KIg-10; TAL-05-0002 | Approved | Bayer AG | Gamunex, Gammaked | United States | Polyradiculoneuropathy, Chronic Inflammatory Demyelinating; Purpura, Thrombocytopenic, Idiopathic; Immunologic Deficiency Syndromes | null | 2003-08-27 | Anxiety Disorders; Corneal Neovascularization; Immunologic Deficiency Syndromes; Kidney Failure, Chronic; Muscular Diseases; Common Variable Immunodeficiency; Neuralgia; Obsessive-Compulsive Disorder; Reflex Sympathetic Dystrophy; Severe Combined Immunodeficiency; Wiskott-Aldrich Syndrome; Autoimmune Diseases; Postural Orthostatic Tachycardia Syndrome; Coronavirus Disease 2019 (COVID-19); Agammaglobulinemia; Tibial Fractures; Primary Immunodeficiency Diseases; Purpura, Thrombocytopenic, Idiopathic; Polyradiculoneuropathy, Chronic Inflammatory Demyelinating; Myasthenia Gravis | Details |
Florapronol (18F) | 18F-FC-119S; 18F-FC-119(S) | Approved | Korea Institute Of Radiological And Medical Sciences, Futurechem | Alzavue | Alzheimer Disease | Details | ||||
Aducanumab | BIIB-037; NI-10; BART | Approved | Neurimmune Ag | ADUHELM | United States | Alzheimer Disease | Biogen Inc | 2021-06-07 | Cognitive Dysfunction; Dementia; Alzheimer Disease | Details |
L-Lysine hydrochloride/Cyanocobalamin/Inositol | Approved | 兴邦 | Malnutrition | Details | ||||||
Immune Globulin Subcutaneous (Human) (Octapharma) | Approved | Octapharma | Cutaquig, Octanorm, Gammanorm | United States | Immunologic Deficiency Syndromes | null | 2018-08-02 | Primary Immunodeficiency Diseases; Dermatomyositis; Immunologic Deficiency Syndromes | Details | |
Florbetaben (18F) | MNI-815; AV-1; ZK-6013443; BAY-949172; 18F-AV-1; 18F-AV1/ZK; AV-1/ZK; BAY 94-9172; UNII-TLA7312TOI | Approved | Piramal | Neuraceq, 欧韦宁 | EU | Alzheimer Disease | Life Radiopharma Berlin Gmbh | 2014-02-20 | Supranuclear Palsy, Progressive; Down Syndrome; Hyponatremia; Immunoglobulin Light-chain Amyloidosis; Contrast agents; Amyloidosis; Alzheimer Disease; Dementia | Details |
Lecanemab | BAN-2401 | Approved | Bioarctic Neuroscience | Leqembi, 乐意保, LEQEMBI | United States | Alzheimer Disease | Eisai Inc | 2023-01-06 | Alzheimer Disease; Cognitive Dysfunction; Dementia | Details |
Florbetapir(18F) | MNI-798; AV-45 | Approved | Eli Lilly And Company | Amyvid | United States | Spasms, Infantile; Rheumatic Diseases; Respiration Disorders; Multiple Sclerosis; Eye Diseases; Collagen Diseases; Skin Diseases; Hypersensitivity | Avid Radiopharmaceuticals Inc | 2012-04-06 | Amyloidosis; Hypersensitivity; Frontotemporal Dementia; Neurodegenerative Diseases; Collagen Diseases; Eye Diseases; Lewy Body Disease; Diagnostic agents; Parkinson Disease; Respiration Disorders; Alzheimer Disease; Rheumatic Diseases; Cognitive Dysfunction; Contrast agents; Spasms, Infantile; Skin Diseases; Multiple Sclerosis; Glioblastoma | Details |
Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
---|---|---|---|---|---|
Buntanetap | ANVS-405; ANVS-401 | Phase 3 Clinical | Raptor Pharmaceutical | Down Syndrome; Chronic Traumatic Encephalopathy; Parkinson Disease; Alzheimer Disease; Cognitive Dysfunction; Frontotemporal Dementia | Details |
Gantenerumab | MAb-31; R-1450; RG-1450; R-04909832 | Phase 3 Clinical | Chugai Pharmaceutical Co Ltd | Alzheimer Disease; Dementia | Details |
Valiltramiprosate | NRM-8499; ALZ-801; BLU-8499 | Phase 3 Clinical | Alzheon Inc | Alzheimer Disease | Details |
Solanezumab | LY-2062430 | Phase 3 Clinical | Eli Lilly And Company | Alzheimer Disease; Dementia; Cognition Disorders | Details |
Birtamimab | NEOD-001 | Phase 3 Clinical | Prothena | Immunoglobulin Light-chain Amyloidosis; Amyloidosis | Details |
Remternetug | LY-3372993 | Phase 3 Clinical | Eli Lilly And Company | Alzheimer Disease | Details |
L-clausenamide | Phase 2 Clinical | Guangzhou Nuohao Pharmaceutical Technology Co Ltd, Fuan Pharmaceutical (Group) Co Ltd, Institue Of Materia Medica Chinese Academy Of Medical Science, Qingdao Huanghai Pharmaceutical Co Ltd | Dementia; Cognitive Dysfunction; Memory Disorders | Details | |
Crenezumab | MABT-5102-A; RG-7412; R-7412; RO-5490245 | Phase 2 Clinical | Ac Immune Sa | Alzheimer Disease | Details |
11C-BF-227 | 11C-BF-227; [11C]BF-227 | Phase 2 Clinical | Tohoku University | Diagnostic agents | Details |
Pittsburgh Compound B | [11C]PIB; [11C]6-OH-BTA-1; 11C-PIB | Phase 2 Clinical | The University Of Utah, University Of Pittsburgh, Ge Healthcare, Uppsala Universitet | Ovarian Neoplasms; Brain Concussion; Breast Neoplasms; Alzheimer Disease; Alcoholism; Dementia; Parkinson Disease | Details |
CT-1812 | CT-1812; SV-119 | Phase 2 Clinical | Cogrx | Alzheimer Disease; Cognitive Dysfunction; Lewy Body Disease; Macular Degeneration | Details |
[18F]THK-5105 | [18F]THK-5105 | Phase 2 Clinical | Tohoku University | Alzheimer Disease | Details |
Edonerpic | T-817 MA | Phase 2 Clinical | Toyama Chemical Co Ltd, Fujifilm Group | Alzheimer Disease; Cognitive Dysfunction; Hepatic Insufficiency | Details |
ABvac-40 | ABvac-40 | Phase 2 Clinical | Araclon Biotech Sl | Alzheimer Disease; Cognitive Dysfunction | Details |
PK-051 | PK051; PK-051 | Phase 2 Clinical | PharmaKure Ltd | Alzheimer Disease; Cognitive Dysfunction | Details |
PRI-002 | RD-2; PRI-002 | Phase 2 Clinical | PRInnovation GmbH, Priavoid | Alzheimer Disease; Cognitive Dysfunction | Details |
18F-92 | 18F-92 | Phase 2 Clinical | First Affiliated Hospital Of Fujian Medical University | Alzheimer Disease | Details |
SHR-1707 | SHR-1707 | Phase 2 Clinical | Shanghai Hengrui Pharmaceutical Co Ltd | Alzheimer Disease | Details |
[18F]THK-5117 | [18F]THK-5117 | Phase 2 Clinical | Tohoku University | Alzheimer Disease | Details |
AD-35 | AD-35 | Phase 2 Clinical | Zhejiang Hisun Pharmaceutical Co Ltd | Alzheimer Disease | Details |
Trontinemab | RO-7126209; RG-6102 | Phase 2 Clinical | F. Hoffmann-La Roche Ltd | Alzheimer Disease | Details |
APH-1105 | APH-1105 | Phase 2 Clinical | Aphios | Dementia; Alzheimer Disease | Details |
RIV-1061-IR | RIV-1061; RIV-1061-IR | Phase 1 Clinical | Revivo Therapeutics | Alzheimer Disease; Cognition Disorders | Details |
A ß antibody Fab | Phase 1 Clinical | Eli Lilly And Company | Alzheimer Disease | Details | |
RQ-9 | AAT-009; RQ-9; RQ-00000009 | Phase 1 Clinical | Pfizer Inc | Dementia | Details |
ASN-120290 | ASN-561; ASN-90; ASN-120290 | Phase 1 Clinical | Merck Serono | Alzheimer Disease; Parkinson Disease | Details |
MDR-1339 | DBT-1339; MDR-1339 | Phase 1 Clinical | Medifron | Alzheimer Disease | Details |
AV-1959D | AV 1959D; AV-1959D | Phase 1 Clinical | Institute For Molecular Medicine, University Of California, Flinders University | Alzheimer Disease | Details |
ALZ-101 | ALZ-101 | Phase 1 Clinical | Alzinova AB | Alzheimer Disease; Dementia | Details |
PRX-012 | PRX-012 | Phase 1 Clinical | Prothena | Alzheimer Disease | Details |
PMN-310 | huPMN-310; PMN-310 | Phase 1 Clinical | ProMIS Neurosciences Inc | Alzheimer Disease; Amyotrophic Lateral Sclerosis; Multiple System Atrophy | Details |
RP-902 | RP902; RP-902 | Phase 1 Clinical | Risen (Suzhou) Pharma Tech Co Ltd | Alzheimer Disease | Details |
ACU-193 | ACU-193; ACU193 | Phase 1 Clinical | Acumen Pharmaceuticals Inc | Alzheimer Disease | Details |
OAB-14 | OAB-14 | Phase 1 Clinical | Shenyang Pharmaceutical University | Alzheimer Disease | Details |
ALN-APP | Phase 1 Clinical | Sirna Therapeutics Inc | Cerebral Amyloid Angiopathy; Spinocerebellar Degenerations; Alzheimer Disease; Neurodegenerative Diseases | Details | |
BEY-2153 | BEY-2153 | Phase 1 Clinical | Beyondbio Inc | Alzheimer Disease | Details |
Abeta42 antibody (Lilly) | Phase 1 Clinical | Eli Lilly And Company | Alzheimer Disease | Details | |
Anatabine citrate | RCP-006 | Clinical | Rock Creek, Roskamp Institute | Thyroiditis, Autoimmune; Smoking Cessation; Tobacco Use Disorder; Alzheimer Disease; Inflammation | Details |
123I-ABC-577 | 123I-ABC-577 | Clinical | Nihon Medi-Physics Co Ltd | Diagnostic agents | Details |
Tarenflurbil spraygel (MIKA Pharma) | Clinical | Galen Ltd, Mika Pharma Gmbh | Pain; Arthritis, Rheumatoid; Skin Diseases; Inflammation; Dermatitis, Atopic | Details | |
Procaine Hydrochloride/Vitamin B6/Inositol | Details | ||||
Inositol/Vitamin B1/Vitamin B2 | Details | ||||
Buntanetap | ANVS-405; ANVS-401 | Phase 3 Clinical | Raptor Pharmaceutical | Down Syndrome; Chronic Traumatic Encephalopathy; Parkinson Disease; Alzheimer Disease; Cognitive Dysfunction; Frontotemporal Dementia | Details |
Gantenerumab | MAb-31; R-1450; RG-1450; R-04909832 | Phase 3 Clinical | Chugai Pharmaceutical Co Ltd | Alzheimer Disease; Dementia | Details |
Valiltramiprosate | NRM-8499; ALZ-801; BLU-8499 | Phase 3 Clinical | Alzheon Inc | Alzheimer Disease | Details |
Solanezumab | LY-2062430 | Phase 3 Clinical | Eli Lilly And Company | Alzheimer Disease; Dementia; Cognition Disorders | Details |
Birtamimab | NEOD-001 | Phase 3 Clinical | Prothena | Immunoglobulin Light-chain Amyloidosis; Amyloidosis | Details |
Remternetug | LY-3372993 | Phase 3 Clinical | Eli Lilly And Company | Alzheimer Disease | Details |
L-clausenamide | Phase 2 Clinical | Guangzhou Nuohao Pharmaceutical Technology Co Ltd, Fuan Pharmaceutical (Group) Co Ltd, Institue Of Materia Medica Chinese Academy Of Medical Science, Qingdao Huanghai Pharmaceutical Co Ltd | Dementia; Cognitive Dysfunction; Memory Disorders | Details | |
Crenezumab | MABT-5102-A; RG-7412; R-7412; RO-5490245 | Phase 2 Clinical | Ac Immune Sa | Alzheimer Disease | Details |
11C-BF-227 | 11C-BF-227; [11C]BF-227 | Phase 2 Clinical | Tohoku University | Diagnostic agents | Details |
Pittsburgh Compound B | [11C]PIB; [11C]6-OH-BTA-1; 11C-PIB | Phase 2 Clinical | The University Of Utah, University Of Pittsburgh, Ge Healthcare, Uppsala Universitet | Ovarian Neoplasms; Brain Concussion; Breast Neoplasms; Alzheimer Disease; Alcoholism; Dementia; Parkinson Disease | Details |
CT-1812 | CT-1812; SV-119 | Phase 2 Clinical | Cogrx | Alzheimer Disease; Cognitive Dysfunction; Lewy Body Disease; Macular Degeneration | Details |
[18F]THK-5105 | [18F]THK-5105 | Phase 2 Clinical | Tohoku University | Alzheimer Disease | Details |
Edonerpic | T-817 MA | Phase 2 Clinical | Toyama Chemical Co Ltd, Fujifilm Group | Alzheimer Disease; Cognitive Dysfunction; Hepatic Insufficiency | Details |
ABvac-40 | ABvac-40 | Phase 2 Clinical | Araclon Biotech Sl | Alzheimer Disease; Cognitive Dysfunction | Details |
PK-051 | PK051; PK-051 | Phase 2 Clinical | PharmaKure Ltd | Alzheimer Disease; Cognitive Dysfunction | Details |
PRI-002 | RD-2; PRI-002 | Phase 2 Clinical | PRInnovation GmbH, Priavoid | Alzheimer Disease; Cognitive Dysfunction | Details |
18F-92 | 18F-92 | Phase 2 Clinical | First Affiliated Hospital Of Fujian Medical University | Alzheimer Disease | Details |
SHR-1707 | SHR-1707 | Phase 2 Clinical | Shanghai Hengrui Pharmaceutical Co Ltd | Alzheimer Disease | Details |
[18F]THK-5117 | [18F]THK-5117 | Phase 2 Clinical | Tohoku University | Alzheimer Disease | Details |
AD-35 | AD-35 | Phase 2 Clinical | Zhejiang Hisun Pharmaceutical Co Ltd | Alzheimer Disease | Details |
Trontinemab | RO-7126209; RG-6102 | Phase 2 Clinical | F. Hoffmann-La Roche Ltd | Alzheimer Disease | Details |
APH-1105 | APH-1105 | Phase 2 Clinical | Aphios | Dementia; Alzheimer Disease | Details |
RIV-1061-IR | RIV-1061; RIV-1061-IR | Phase 1 Clinical | Revivo Therapeutics | Alzheimer Disease; Cognition Disorders | Details |
A ß antibody Fab | Phase 1 Clinical | Eli Lilly And Company | Alzheimer Disease | Details | |
RQ-9 | AAT-009; RQ-9; RQ-00000009 | Phase 1 Clinical | Pfizer Inc | Dementia | Details |
ASN-120290 | ASN-561; ASN-90; ASN-120290 | Phase 1 Clinical | Merck Serono | Alzheimer Disease; Parkinson Disease | Details |
MDR-1339 | DBT-1339; MDR-1339 | Phase 1 Clinical | Medifron | Alzheimer Disease | Details |
AV-1959D | AV 1959D; AV-1959D | Phase 1 Clinical | Institute For Molecular Medicine, University Of California, Flinders University | Alzheimer Disease | Details |
ALZ-101 | ALZ-101 | Phase 1 Clinical | Alzinova AB | Alzheimer Disease; Dementia | Details |
PRX-012 | PRX-012 | Phase 1 Clinical | Prothena | Alzheimer Disease | Details |
PMN-310 | huPMN-310; PMN-310 | Phase 1 Clinical | ProMIS Neurosciences Inc | Alzheimer Disease; Amyotrophic Lateral Sclerosis; Multiple System Atrophy | Details |
RP-902 | RP902; RP-902 | Phase 1 Clinical | Risen (Suzhou) Pharma Tech Co Ltd | Alzheimer Disease | Details |
ACU-193 | ACU-193; ACU193 | Phase 1 Clinical | Acumen Pharmaceuticals Inc | Alzheimer Disease | Details |
OAB-14 | OAB-14 | Phase 1 Clinical | Shenyang Pharmaceutical University | Alzheimer Disease | Details |
ALN-APP | Phase 1 Clinical | Sirna Therapeutics Inc | Cerebral Amyloid Angiopathy; Spinocerebellar Degenerations; Alzheimer Disease; Neurodegenerative Diseases | Details | |
BEY-2153 | BEY-2153 | Phase 1 Clinical | Beyondbio Inc | Alzheimer Disease | Details |
Abeta42 antibody (Lilly) | Phase 1 Clinical | Eli Lilly And Company | Alzheimer Disease | Details | |
Anatabine citrate | RCP-006 | Clinical | Rock Creek, Roskamp Institute | Thyroiditis, Autoimmune; Smoking Cessation; Tobacco Use Disorder; Alzheimer Disease; Inflammation | Details |
123I-ABC-577 | 123I-ABC-577 | Clinical | Nihon Medi-Physics Co Ltd | Diagnostic agents | Details |
Tarenflurbil spraygel (MIKA Pharma) | Clinical | Galen Ltd, Mika Pharma Gmbh | Pain; Arthritis, Rheumatoid; Skin Diseases; Inflammation; Dermatitis, Atopic | Details | |
Procaine Hydrochloride/Vitamin B6/Inositol | Details | ||||
Inositol/Vitamin B1/Vitamin B2 | Details |
This web search service is supported by Google Inc.